Conivaptan: new treatment for hyponatremia
1Yale-New Haven Hospital, New Haven, CT, USA.
Summary
Conivaptan effectively treats euvolemic hyponatremia by increasing serum sodium and water clearance. This vasopressin antagonist offers a new option for resistant cases, though long-term safety is still under evaluation.
Area of Science:
- Pharmacology and Therapeutics
- Nephrology
- Cardiology
Background:
- Euvolemic hyponatremia is a complex condition often requiring novel therapeutic approaches.
- Vasopressin plays a key role in water balance, making its receptors targets for treatment.
Purpose of the Study:
- To discuss the pharmacology, pharmacokinetics, clinical efficacy, safety, and administration of conivaptan.
- To evaluate conivaptan as a treatment for euvolemic hyponatremia.
Main Methods:
- Review of pharmacology, bioavailability, and pharmacokinetics.
- Analysis of data from three double-blind, placebo-controlled, randomized, multicenter studies.
- Evaluation of clinical efficacy, adverse effects, and drug interactions.
Main Results:
- Conivaptan demonstrated efficacy in increasing serum sodium levels.
- The drug was effective in enhancing water clearance.
- Conivaptan was generally well tolerated in clinical trials.
Conclusions:
- Conivaptan is the first approved vasopressin antagonist for euvolemic hyponatremia.
- It offers a new treatment option for resistant hyponatremia via free-water excretion.
- Further studies are needed to fully establish long-term safety and effects.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:29Diabetes Insipidus I: Introduction
Definition Diabetes insipidus is a disorder marked by the production of large amounts of dilute urine because of impaired vasopressin production, release, or kidney response. The lack of effective vasopressin action limits water reabsorption in the renal collecting ducts, which leads to excessive urinary water loss and intense thirst.Clinical PresentationIndividuals with diabetes insipidus report persistent thirst and very high urine output. In severe cases, fluid intake can reach up to 20...
01:22Diabetes Insipidus II: Pathophysiology
Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...